Patents by Inventor Shahriar Mobashery
Shahriar Mobashery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230293488Abstract: The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.Type: ApplicationFiled: December 8, 2022Publication date: September 21, 2023Inventors: Gautam Dantas, Patrick Gonzales, Kevin Forsberg, Mitchell Pesesky, Mayland Chang, Shahriar Mobashery
-
Publication number: 20230271950Abstract: Here we report the discovery of 2-(4-(3-(trifluoromethoxy)phenoxy)picolinamido)benzo[d]oxazole-5-carboxylate as an antibacterial with potent and selective activity against C. difficile. Its MIC50 and MIC90 values, documented across 101 strains of C. difficile, are 0.12 and 0.25 ?g/mL, respectively. The compound is effective against C. difficile both at the logarithmic (vegetative) and stationary phases of growth. It targets cell-wall biosynthesis, as assessed both by macromolecular biosynthesis assays and by scanning-electron microscopy. Animals infected with a lethal dose of C. difficile and treated with compound 1 had better survival compared to treatment with vancomycin, which is the front-line antibiotic used for severe recurrent C. difficile infection.Type: ApplicationFiled: June 28, 2021Publication date: August 31, 2023Applicant: University of Notre Dame Du LacInventors: Shahriar MOBASHERY, Mayland CHANG, Enrico SPERI
-
Patent number: 11559514Abstract: The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.Type: GrantFiled: October 29, 2019Date of Patent: January 24, 2023Assignees: Washington University, University of Notre Dame du LacInventors: Gautam Dantas, Patrick Gonzales, Kevin Forsberg, Mitchell Pesesky, Mayland Chang, Shahriar Mobashery
-
Patent number: 11168062Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.Type: GrantFiled: September 12, 2017Date of Patent: November 9, 2021Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery, Derong Ding
-
Publication number: 20210340117Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.Type: ApplicationFiled: July 15, 2021Publication date: November 4, 2021Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY, Derong DING
-
Publication number: 20210340116Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.Type: ApplicationFiled: July 15, 2021Publication date: November 4, 2021Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY, Derong DING
-
Patent number: 10662164Abstract: The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.Type: GrantFiled: September 25, 2015Date of Patent: May 26, 2020Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery, Edward Spink, Derong Ding, Sebastian Testero, Erika Leemans, Marc Boudreau
-
Publication number: 20200054605Abstract: The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.Type: ApplicationFiled: October 29, 2019Publication date: February 20, 2020Inventors: Gautam Dantas, Patrick Gonzales, Kevin Forsberg, Mitchell Pesesky, Mayland Chang, Shahriar Mobashery
-
Patent number: 10500191Abstract: The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.Type: GrantFiled: July 8, 2016Date of Patent: December 10, 2019Assignee: WASHINGTON UNIVERSITYInventors: Gautam Dantas, Patrick Gonzales, Kevin Forsberg, Mitchell Pesesky, Mayland Chang, Shahriar Mobashery
-
Patent number: 10357546Abstract: The invention provides compounds, compositions, and methods to improve or accelerate the healing of a wound. In various embodiments, the methods can include the topical treatment of the wound with the enzyme MMP-8, or the topical treatment of the wound with MMP-8 in combination with administration of an MMP-9 inhibitor, to accelerate the healing of the wound.Type: GrantFiled: September 21, 2015Date of Patent: July 23, 2019Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery
-
Publication number: 20190210984Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.Type: ApplicationFiled: September 12, 2017Publication date: July 11, 2019Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY, Derong DING
-
Patent number: 10329262Abstract: A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed (Formula V). Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.Type: GrantFiled: October 2, 2017Date of Patent: June 25, 2019Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery, Renee Bouley
-
Publication number: 20190127340Abstract: The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.Type: ApplicationFiled: September 25, 2015Publication date: May 2, 2019Inventors: Mayland CHANG, Shahriar Mobashery, Edward Spink, Derong Ding, Sebastian Testero, Erika Leemans, Marc Boudreau
-
Patent number: 10253013Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.Type: GrantFiled: April 24, 2018Date of Patent: April 9, 2019Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery
-
Publication number: 20180237412Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY
-
Publication number: 20180200226Abstract: The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.Type: ApplicationFiled: July 8, 2016Publication date: July 19, 2018Inventors: Gautam Dantas, Patrick Gonzales, Kevin Forsberg, Mitchell Pesesky, Mayland Chang, Shahriar Mobashery
-
Patent number: 9951035Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.Type: GrantFiled: March 24, 2017Date of Patent: April 24, 2018Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery
-
Publication number: 20180044316Abstract: We disclose herein that the BlaR1 protein of methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic sensor/signal transducer, is phosphorylated on exposure to ?-lactam antibiotics. This event is critical for the onset of the biochemical events that unleash induction of antibiotic resistance. The BlaR1 phosphorylation and the antibiotic-resistance phenotype are abrogated in the presence of inhibitors described herein that restore susceptibility of the organism to ?-lactam antibiotics. The invention thus provides compounds and methods for abrogating antibiotic resistance to ?-lactam antibiotics and for treating infections causes by antibiotics prone to developing resistance.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Shahriar MOBASHERY, Marc A. BOUDREAU
-
Publication number: 20180029997Abstract: A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.Type: ApplicationFiled: October 2, 2017Publication date: February 1, 2018Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY, Renee BOULEY
-
Patent number: 9867805Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.Type: GrantFiled: April 26, 2016Date of Patent: January 16, 2018Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee